- CLINICAL DATA BUILDS UPON BODY OF EVIDENCE SUGGESTING EXS-21546 IS A HIGHLY POTENT AND SELECTIVE A2AR INHIBITOR WITH LOW CNS EXPOSURE
- EXSCIENTIA ANTICIPATES INITIATING PHASE 1B/2 IN PATIENTS WITH HIGH ADENOSINE SIGNATURE CANCERS IN SECOND HALF OF 2022
- ONGOING TRANSLATIONAL WORK TO ESTABLISH PREDICTIVE BIOMARKER TO ENABLE TARGETING OF PATIENTS MOST LIKELY TO BENEFIT FROM EXS-21546
Oxford, UK, 14 June 2022:
Evotec’s partner Exscientia plc (NASDAQ: EXAI) today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2a receptor antagonist co-invented and developed through a collaboration between Exscientia and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO). Topline data from this healthy volunteer study confirmed Exscientia’s target product profile design, including potency, high receptor selectivity and expected low brain exposure with no CNS adverse events reported, supporting advancement of EXS-21546 to a Phase 1b/2 study in patients with solid tumours exhibiting high adenosine signatures.
Please follow this link to the full press release from Exscientia.